RT Journal Article
SR Electronic
T1 Development and Multicenter Performance Evaluation of The First Fully Automated SARS-CoV-2 IgM and IgG Immunoassays
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20067231
DO 10.1101/2020.04.16.20067231
A1 Chungen Qian
A1 Mi Zhou
A1 Fangming Cheng
A1 Xiaotao Lin
A1 Yijun Gong
A1 Xiaobing Xie
A1 Ping Li
A1 Zhiyong Li
A1 Pingan Zhang
A1 Zejin Liu
A1 Fang Hu
A1 Yun Wang
A1 Quan Li
A1 Yan Zhu
A1 Guikai Duan
A1 Yinting Xing
A1 Huanyu Song
A1 Wenfang Xu
A1 Bi-Feng Liu
A1 Fuzhen Xia
YR 2020
UL http://medrxiv.org/content/early/2020/04/21/2020.04.16.20067231.abstract
AB BACKGROUND The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally. The laboratory diagnosis of SARS-CoV-2 infection has relied on nucleic acid tests. However, there are many limitations of nucleic acid tests, including low throughput and high rates of false negatives. More sensitive and accurate tests to effectively identify infected patients are needed.METHODS This study has developed fully automated chemiluminescent immunoassays (CLIA) to determine IgM and IgG antibodies to SARS-CoV-2 in human serum. The assay performance has been evaluated at 10 hospitals. Clinical specificity was evaluated by measuring 972 hospitalized patients with diseases other than COVID-19, and 586 donors of a normal population. Clinical sensitivity was assessed on 503 confirmed cases of SARS-CoV-2 by RT-PCR and 52 suspected cases.RESULTS The assays demonstrated satisfied assay precision with coefficient of variation (CV) of less than 4.45%. Inactivation of specimen does not affect assay measurement. SARS-CoV-2 IgM shows clinical specificity of 97.33% and 99.49% for hospitalized patients and normal population respectively. SARS-CoV-2 IgG shows clinical specificity of 97.43% and 99.15% for the hospitalized patients and the normal population respectively. SARS-CoV-2 IgM and IgG show clinical sensitivity of 85.88% and 96.62% respectively for confirmed SARS-Cov-2 infection with RT-PCR, of 73.08% and 86.54% respectively for suspected cases.CONCLUSIONS we have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum. The assays demonstrated high clinical specificity and sensitivity, and add great value to nucleic acid testing in fighting against the global pandemic of the SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementB.F. Liu, Fundamental Research Funds for the Central Universities (2020kfyXGYJ103).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author on reasonable request.SARS-CoV-2severe acute respiratory syndrome coronavirus 2COVID-19novel coronavirus diseaseCLIAchemiluminescent immunoassayRT-PCRReal Time-PCR